The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Fedin A.I.

Pirogov Russian National Research Medical University

Mkhitaryan E.A.

Pirogov Russian National Research Medical University;
Russian Clinical and Research Center of Gerontology Pirogov — Russian National Research Medical University

Pharmacotherapy approaches to vascular mild cognitive impairment in patients of different age groups

Authors:

Zaharov V.V., Fedin A.I., Mkhitaryan E.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(10): 26‑32

DOI: 10.17116/jnevro202312310126

Read: 2360 times

Contact the author
Table of contents

PHARMACOTHERAPY APPROACHES TO VASCULAR MILD COGNITIVE IMPAIRMENT IN PATIENTS OF DIFFERENT AGE GROUPS
PHARMACOTHERAPY APPROACHES TO VASCULAR MILD COGNITIVE IMPAIRMENT IN PATIENTS OF DIFFERENT AGE GROUPS

To cite this article:

Zaharov VV, Fedin AI, Mkhitaryan EA. Pharmacotherapy approaches to vascular mild cognitive impairment in patients of different age groups. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(10):26‑32. (In Russ.)
https://doi.org/10.17116/jnevro202312310126

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Prevalence and characteristics of risk factors for cere­brovascular disease in overweight. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):118-124
Resu­lts of the inte­rnational multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the effi­cacy and safety of the sequential therapy with ethy­lmethylhydroxypyridine succinate in patients in the acute and early reco­very periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Study of drug-drug inte­ractions between Mexi­dol and thro­mbolytic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):139-144
Improving the quality of life and the possibility of pathogenetic therapy in adult patients with cere­bral palsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):75-84
The impact of Mexi­dol on improving quality of life para­meters and functional kidney status as part of complex therapy for cognitive impairments in como­rbid patients with microalbuminuria against the background of arte­rial hype­rtension and type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):478-478
The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59
Free radi­cals in reproductive processes. Russian Journal of Human Reproduction. 2025;(5):51-57
Abstract:

The article discusses the possibilities of pharmacotherapy of moderate vascular cognitive impairment in different age groups. The results of a double-blind randomized clinical trial «MEMO» using the antioxidant and antihypoxic drug Mexidol are presented. On the basis of cognitive scales, when using a sequential course of parenteral and oral administration of mexidol, its reliable effectiveness was shown in each of the three analyzed groups: 40—60 years old, 61—75 years old and 76—90 years old. Mexidol showed an optimal safety profile in all age groups.

Keywords:

vascular mild cognitive impairment
chronic brain ischemia
antioxidants
Mexidol

Authors:

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Fedin A.I.

Pirogov Russian National Research Medical University

Mkhitaryan E.A.

Pirogov Russian National Research Medical University;
Russian Clinical and Research Center of Gerontology Pirogov — Russian National Research Medical University

Received:

22.08.2023

Accepted:

24.08.2023

Close metadata

References:

  1. Krivanek TJ, Gale SA, McFeeley BM, et al. Promoting Successful Cognitive Aging: A Ten-Year Update. J Alzheimers Dis. 2021;81(3):871-920.  https://doi.org/10.3233/JAD-201462
  2. The population of the Russian Federation by gender and age as of January 1, 2021. The link is available on 06/23/2023. (In Russ.). https://rosstat.gov.ru/storage/mediabank/Bul_chislen_nasel-pv_01-01-2021.pdf
  3. Ukkonen M, Jämsen E, Zeitlin R, et al. Emergency department visits in older patients: a population-based survey. BMC Emerg Med. 2019;19(1):20.  https://doi.org/10.1186/s12873-019-0236-3
  4. Wetterberg H, Najar J, Rydén L, et al. Dementia remains the major predictor of death among octogenarians. A study of two population cohorts of 85-year-olds examined 22 years apart. Eur J Epidemiol. 2021;36(5):507-517.  https://doi.org/10.1007/s10654-021-00745
  5. GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990—2016: A systematic analysis for the Global Burden of Disease Study. Lancet Neurol. 2016;23(18):459-480. 
  6. Mkhitaryan EA, Vorobieva NM, Tkacheva ON, et al. Prevalence of cognitive impairments and their association with socioeconomic, demographic and anthropometric factors and geriatric syndromes in persons over 65 years of age: data from the Russian epidemiological study EUCALYPTUS. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):44-53. (In Russ.). https://doi.org/10.14412/2074-2711-2022-3-44-53
  7. Kostev K, Osina G. Treatment Patterns of Patients with All-Cause Dementia In Russia. J Alzheimers Dis Rep. 2020;4(1):9-14.  https://doi.org/10.3233/ADR-190144
  8. Pilipovich AA, Vorobieva OV. Moderate cognitive disorders: modern aspects of diagnosis and therapy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(11):124-130. (In Russ.). https://doi.org/10.17116/jnevro2020120111124
  9. Starchina YuA. Non-Demented Cognitive Impairment: A Modern View On The Problem. Neurology, Neuropsychiatry, Psychosomatics. 2017;9(2):71-76. (In Russ.).
  10. Eshkoor SA, Hamid TA, Mun CY, et al. Mild cognitive impairment and its management in older people. Clin Interv Aging. 2015;10:687-693.  https://doi.org/10.2147/CIA.S73922
  11. Jongsiriyanyong S, Limpawattana P. Mild Cognitive Impairment in Clinical Practice: A Review Article. Am J Alzheimers Dis Other Demen. 2018;33(8):500‐507.  https://doi.org/10.1177/1533317518791401
  12. Shchepankevich LA, Gribacheva IA, Popova TF, et al. Questions of therapy of moderate cognitive impairments. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):110-114. (In Russ.). https://doi.org/10.14412/2074-2711-2022-6-110-114
  13. Novikova MS, Zakharov VV, Vakhnina NV. The effectiveness of a combination of non-drug methods in patients with non-dementic vascular cognitive impairment. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(1):57-64. (In Russ.). https://doi.org/10.14412/2074-2711-2023-1-57-64
  14. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomized controlled trial. Lancet. 2015;385(9984):2255-2263. https://doi.org/10.1016/S0140-6736(15)60461-5
  15. Cummings J. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer’s Disease. J Neuropsychiatry Clin Neurosci. 2021;33(1):3-13.  https://doi.org/10.1176/appi.neuropsych.20060152
  16. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.  https://doi.org/10.1186/alzrt269
  17. Linton AE, Weekman EM, Wilcock DM. Pathologic sequelae of vascular cognitive impairment and dementia sheds light on potential targets for intervention. Cereb Circ Cogn Behav. 2021;2:100030. https://doi.org/10.1016/j.cccb.2021.100030
  18. Vemuri P, Knopman DS. The role of cerebrovascular disease when there is concomitant Alzheimer disease. Biochim Biophys Acta. 2016;1862(5):952-956.  https://doi.org/10.1016/j.bbadis.2015.09.013
  19. Nikolenko VN, Rizaeva NA, Bulygin KV, et al. The role of oxidative stress in the development of Alzheimer’s disease. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(4):68-74. (In Russ.). https://doi.org/10.14412/2074-2711-2022-4-68-74
  20. Fedin AI, Zakharov VV, Tanyashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of sequential therapy of patients with chronic cerebral ischemia with Mexidol and Mexidol forte 250 (MEMO study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
  21. Zakharov VV, Tkacheva ON, Mkhitaryan EA, Fedin AI. The effectiveness of Mexidol in patients of different age groups with chronic cerebral ischemia and cognitive impairment (results of a sub-analysis of the international multicenter randomized, double-blind, placebo-controlled study MEMO). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(11-2):1-8. (In Russ.). https://doi.org/10.17116/jnevro202212211273https://doi.org/10.17116/jnevro2022121121
  22. Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized, double-blind, multicenter, placebo-controlled, parallel-group study of the efficacy and safety of mexidol in long-term sequential therapy in patients in the acute and early recovery periods. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
  23. Chukanova EI, Chukanova AS. Efficacy and safety of Mexidol FORTE 250 in sequential therapy in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
  24. Zhuravleva MV, Prokofiev AB, Serebrova SYu, et al. Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(6):119-124. (In Russ.). https://doi.org/10.17116/jnevro2020120061119
  25. Oganov RG. Positive experience of using ethylmethylhydroxypyridine succinate in the treatment of cardiac patients. Cardiovascular therapy and prevention. 2017;16(5):91-94. (In Russ.). https://doi.org/10.15829/1728-8800-2017-5-91-94
  26. Tolkacheva VV, Kazakhmedov ER, Kobalava ZhD, et al. Influence of Mexidol on the quality of life and functional status of patients with chronic cerebral ischemia and chronic heart failure with low ejection fraction. Cardiology and Cardiovascular Surgery. 2021;14(1):80-89. (In Russ.). https://doi.org/10.17116/kardio20211401180
  27. Martynov MYu, Zhuravleva MV, Vasyukova NS, et al. Oxidative stress in the pathogenesis of cerebral stroke and its correction. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2023;123(1):16-27. (In Russ.). https://doi.org/10.17116/jnevro202312301116
  28. Zhuravleva MV, Kamchatnov PR, Vasyukova NS, et al. Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate preparations in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(11):29-39. (In Russ.). https://doi.org/10.17116/jnevro202212211129
  29. Leonova ES, Polyakov SV, Pozdnyakova MA, et al. Experience in neuroprotective therapy of primary open-angle glaucoma based on the use of various forms of Mexidol. Bulletin of Ophthalmology. 2015;6:90-93. (In Russ.).
  30. Movsisyan AB, Oganezova ZhG, Egorov EA, et al. Possibilities and results of using antioxidant therapy in ophthalmic practice. Bulletin of Ophthalmology. 2022;138(5):122-128. (In Russ.). https://doi.org/10.17116/oftalma2022138051126https://doi.org/10.17116/oftalma2022138051122
  31. Ushkalova EA, Zyryanov SK, Butranova OI. Safety of Mexidol® (ethylmethylhydroxypyridine succinate) in adult patients of different age groups. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):77-82. (In Russ.). https://doi.org/10.14412/2074-2711-2022-5-77-82
  32. Stakhovskaya LV, Mkhitaryan EA, Tkacheva ON, et al. Efficacy and safety of mexidol in patients of different age groups in the acute and early recovery periods of hemispheric ischemic stroke (results of a subanalysis of a randomized, double-blind, multicenter, placebo-controlled study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(8-2):49-57. (In Russ.). https://doi.org/10.17116/jnevro202012008249
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.